Here's Why You Should Add Inogen Stock to Your Portfolio Now

Inogen (INGN) posted strong Q2 2025 results with a 4% revenue increase, notably driven by 19.3% domestic and 17.7% international B2B sales growth, and projects 37.5% earnings growth for 2025 with revenue guidance implying 6% growth, supported by new product launches like Voxi 5 and FDA-cleared Simeox, and strategic partnerships for global market expansion. Despite an attractive 0.7x P/S ratio compared to the industry's 2.7x within the growing portable oxygen concentrator market, the company faces challenges from direct-to-consumer channel seasonality and foreign exchange volatility impacting international revenues.

Analysis

Inogen (INGN) is demonstrating a strategic pivot toward its business-to-business (B2B) channels, which are driving current growth and offsetting weakness in its direct-to-consumer (DTC) segment. The company's second-quarter results showed a 4% year-over-year revenue increase, underpinned by robust B2B sales growth of 19.3% in the U.S. and 17.7% internationally. This performance supports the updated full-year 2025 revenue guidance of $354-$357 million, implying approximately 6% growth. Future growth catalysts are centered on an expanding product portfolio, including the recent launch of the Voxi 5, the anticipated revenue contribution from the Rove 4, and FDA clearance for Simeox. Furthermore, a strategic collaboration with Yuwell is positioned to facilitate entry into the Chinese market and enhance R&D, a key long-term driver. Despite these positive developments and a favorable valuation with a Price-to-Sales ratio of 0.7x compared to the industry's 2.7x, several risks persist. The DTC channel faces ongoing pressure from seasonal softness and advertising headwinds, while significant international revenue remains exposed to foreign exchange volatility, which already negatively impacted Q2 international sales by 10 basis points.

Key Decisions for Investors

• Investors could consider Inogen an attractive value proposition, given its price-to-sales ratio of 0.7x is well below the industry average of 2.7x, coupled with strong B2B channel growth and a clear product pipeline.
• It is critical to monitor the performance of the direct-to-consumer channel for signs of stabilization and track the impact of foreign exchange fluctuations, as these represent the primary headwinds to the company's growth outlook.
• The investment thesis is contingent on the long-term success of new product launches and the strategic entry into the Chinese market, suggesting that investors should evaluate the stock based on its 2025 growth prospects rather than near-term volatility.